GLP-1 Maintenance Dosing: What Long-Term Use Looks Like

By the time a STEP trial participant reached week 68, the question of "are you losing weight?" had largely been answered. The more interesting question, which the original STEP 1 protocol was not designed to address, was what would happen if they simply kept taking the medication.

STEP 5 was built to answer that question. The trial, led by W. Timothy Garvey at the University of Alabama at Birmingham and published in Nature Medicine in 2022, followed patients on 2.4 mg weekly semaglutide for 104 weeks — two full years. The results reframed what maintenance dosing actually looks like.

What STEP 5 actually showed

Three hundred and four patients were randomised to either semaglutide 2.4 mg weekly or placebo for two years, with structured lifestyle counselling for both arms. Weight loss in the semaglutide group reached approximately 15% by week 60 — consistent with the original STEP 1 results — and was then sustained, with a small additional drift downward, through week 104. Mean weight loss at the two-year mark was 15.2% in the treatment arm versus 2.6% in placebo.

The trajectory matters as much as the endpoint. The weight loss curve plateaued at roughly 60–80 weeks and then held. There was no late-stage drift back upward in the treatment arm — the body did not eventually "break through" the suppression. Cardiometabolic improvements (waist circumference, lipids, glycaemic markers, blood pressure) tracked the weight and remained improved through year two.

Side effects followed the pattern seen in the shorter trials. Gastrointestinal effects clustered in the first 20 weeks of titration and largely resolved or became manageable thereafter. Discontinuation rates from adverse events were modest. The two-year safety profile largely resembled the one-year profile, which was reassuring for the framing of GLP-1 therapy as chronic treatment rather than a finite intervention.

SUSTAIN and longer-term diabetes data

The diabetes literature provides a complementary view, because many patients have been on semaglutide for type 2 diabetes since well before the obesity indication existed. The SUSTAIN programme, which evaluated semaglutide at lower doses (0.5 mg and 1.0 mg) for diabetes, generated several years of continuous-use safety data. The cardiovascular outcomes trial SUSTAIN-6, led by Steven Marso, demonstrated reduced major adverse cardiovascular events in patients with diabetes and high cardiovascular risk on semaglutide — an important signal for long-term benefit beyond weight reduction.

What the maintenance dose actually does

The 2.4 mg weekly dose was selected for the obesity indication because it produced the largest weight loss in the dose-finding studies that preceded STEP 1. The pharmacology at that dose involves several converging mechanisms.

Central appetite suppression is the dominant effect. Semaglutide crosses into key hypothalamic and brainstem nuclei — the arcuate nucleus, the area postrema, the nucleus tractus solitarius — that integrate hunger and satiety signalling. Daniel Drucker at the University of Toronto, who has been mapping GLP-1 biology since the early 1990s, has documented the central nervous system pathways in detail. The result, for patients, is sustained appetite reduction rather than the peak-and-trough pattern of pre-meal hunger.

Slowed gastric emptying is a second mechanism, particularly prominent in the first months of treatment, that contributes to early satiety and reduced meal size. This effect attenuates somewhat with continued exposure but does not fully disappear.

Reward attenuation — the "food noise" reduction patients describe — is increasingly recognised as a third mechanism. Liselotte van Bloemendaal at VU University Medical Center Amsterdam published fMRI evidence that GLP-1 receptor activation reduces brain reward responses to food cues. The neuroscience of food reward modulation is one of the more distinctive features of GLP-1 therapy and one of the most-reported subjective changes during maintenance.

Dose-reduction strategies in practice

Between "stay on 2.4 mg indefinitely" and "stop entirely" sits the clinical middle ground of lower-dose maintenance. The randomised evidence base for sub-2.4 mg semaglutide in obesity treatment is limited — most trials used the full dose throughout. But observational data and clinical practice have generated a working pattern.

Some patients who reach their target weight on 2.4 mg find they can maintain on 1.7 mg or 1.0 mg with comparable weight stability. Others drift upward at the lower dose and return to 2.4 mg. There is no reliable predictor for which group a given patient will fall into, though several signals appear in clinical experience: patients with lower baseline BMI, those who reach target weight more easily, and those with stronger behavioural anchors tend to maintain better at reduced doses.

The tirzepatide range is wider: maintenance doses of 5 mg, 10 mg, and 15 mg weekly are all FDA-approved, and dose reduction from a higher dose to a lower one is a common strategy after target weight is reached. Garvey's clinical writing has described stepping protocols that work backwards through the titration ladder rather than continuing at peak dose indefinitely.

The honest framing for patients is that lower-dose maintenance is plausible but not guaranteed. Decisions involve clinical judgement and individual experimentation rather than algorithmic certainty. Strategies for tapering or discontinuing entirely sit further along the same continuum.

The chronic disease frame

The data from STEP 1, STEP 4, STEP 5, SURMOUNT-1, SURMOUNT-4, and the SUSTAIN programme converge on a coherent clinical picture. While patients are on a sufficient dose of a GLP-1 receptor agonist, weight loss is achievable and maintainable. When the medication stops, the underlying biology — elevated ghrelin, suppressed satiety hormones, reduced resting metabolic rate — reasserts itself and weight regain follows.

This pattern is the chronic disease model in action. Hypertension medications lower blood pressure while taken; stopping them raises blood pressure. Statins lower LDL while taken; stopping them raises LDL. GLP-1 medications reduce weight while taken; stopping them allows regain. The mechanism is not unique to obesity, but the framing of obesity as a treatable chronic condition is comparatively recent — the American Medical Association formally adopted that position only in 2013.

For maintenance dosing specifically, the implication is that long-term treatment is the default expectation rather than a fallback. Patients and clinicians make decisions about duration, dose, and discontinuation based on benefits, side effects, cost, and personal preference — but the biological default, given the available evidence, is ongoing therapy. The data on discontinuation is part of why that default has settled where it has.

What patients describe at the two-year mark

Quality-of-life data from STEP 5 and from observational cohorts in the years since FDA approval describe a fairly stable subjective experience by the second year. The dramatic appetite reduction of the first months has largely settled into a quieter, sustained reduction. Food preoccupation remains lower than pre-treatment. Energy levels, sleep, and physical function are typically better than baseline, mostly mediated by weight loss but with some direct effects.

The side effects that dominated early treatment — nausea, constipation, fatigue — are usually well-managed or absent. A subset of patients continue to experience them episodically, particularly after missed doses or dietary triggers. The long-term safety signals from STEP 5 and from the larger SUSTAIN diabetes database are reassuring but not definitive — five-year and ten-year data continue to accumulate as more patients enter long-term treatment.

The clinical maturity of GLP-1 therapy for obesity is still developing. STEP 5's two-year data was the first dedicated long-term obesity trial; longer extensions are underway. For now, the available evidence supports sustained treatment as the expected clinical pattern, with dose-reduction strategies as a reasonable secondary option for patients who reach their target weight and want to explore the lower end of the maintenance range.

Key takeaways

• STEP 5 followed patients on 2.4 mg semaglutide for 104 weeks and found sustained weight loss of approximately 15% at the two-year mark, with no late-stage drift upward.
• Cardiometabolic improvements (waist, lipids, glucose, blood pressure) tracked weight loss and persisted through year two.
• The 2.4 mg dose was selected because it produced the largest weight loss in dose-finding studies; lower doses are plausible for maintenance but the randomised evidence is limited.
• Dose-reduction strategies — 1.7 mg or 1.0 mg semaglutide, or stepping down through the tirzepatide ladder — are clinically common after target weight is reached.
• Long-term treatment is the default expectation in the chronic disease framing of obesity; STEP 4 and SURMOUNT-4 confirmed that stopping leads to regain.
• Subjective patient experience at the two-year mark tends to involve a quieter, sustained appetite reduction with manageable or absent side effects after the early titration period.